Repository logo
 

Metastatic-niche labelling reveals parenchymal cells with stem features.

Accepted version
Peer-reviewed

Change log

Authors

Ombrato, Luigi 
Nolan, Emma 
Kurelac, Ivana 
Mavousian, Antranik 
Bridgeman, Victoria Louise 

Abstract

Direct investigation of the early cellular changes induced by metastatic cells within the surrounding tissue remains a challenge. Here we present a system in which metastatic cancer cells release a cell-penetrating fluorescent protein, which is taken up by neighbouring cells and enables spatial identification of the local metastatic cellular environment. Using this system, tissue cells with low representation in the metastatic niche can be identified and characterized within the bulk tissue. To highlight its potential, we applied this strategy to study the cellular environment of metastatic breast cancer cells in the lung. We report the presence of cancer-associated parenchymal cells, which exhibit stem-cell-like features, expression of lung progenitor markers, multi-lineage differentiation potential and self-renewal activity. In ex vivo assays, lung epithelial cells acquire a cancer-associated parenchymal-cell-like phenotype when co-cultured with cancer cells and support their growth. These results highlight the potential of this method as a platform for new discoveries.

Description

Keywords

Animals, Breast Neoplasms, Cell Differentiation, Cell Lineage, Cell Tracking, Coculture Techniques, Epithelial Cells, Female, Humans, Luminescent Proteins, Lung Neoplasms, Male, Mice, Neoplasm Metastasis, Neoplastic Stem Cells, Neutrophils, Organoids, Parenchymal Tissue, Staining and Labeling, Stem Cell Niche, Tumor Microenvironment, Red Fluorescent Protein

Journal Title

Nature

Conference Name

Journal ISSN

0028-0836
1476-4687

Volume Title

572

Publisher

Springer Science and Business Media LLC

Rights

All rights reserved
Sponsorship
Wellcome Trust (107633/Z/15/Z)
European Research Council (679411)
Medical Research Council (MC_PC_12009)
This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001112), the UK Medical Research Council (FC001112), and the Wellcome Trust (FC001112) and the European Research Council grant (ERC CoG-H2020-725492); and by the Wellcome Trust – MRC Stem Cell Institute which receives funding from the Sir Henry Dale Fellowship from Wellcome and the Royal Society (107633/Z/15/Z) and the European Research Council Starting Grant (679411).